ArticleNature2022
Landscape of helper and regulatory antitumour CD4
Open access · greenAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers.
0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed
14.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed, 178 citations in OpenAlex.
- Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma.Journal for immunotherapy of cancer · 2026Trial
- Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma.Cell reports. Medicine · 2025Trial
- Pleiotropic effects of BET inhibition broadly boost tumor immunogenicity to CD8Oncoimmunology · 2026Article
- Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.Nature medicine · 2026Article
- Entering the Age of Specificity in T Cell Immunity.Immunological reviews · 2026Review
- Molecular heterogeneity and clonal origin of CCR8Nature communications · 2026Article
- Clonal sharing and plasticity of follicular CD4 + T cells across lymph nodes and tumors in non-small cell lung cancer.Nature communications · 2026Article
- Cell surface ADGRG1 and CD86 expression identifies antitumor CD4Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Article
- The T Cell Receptor: Molecular Sensor, Therapeutic Mediator and Probabilistic Driver of Adaptive Immunity.Immunological reviews · 2026Review
- CD4Science (New York, N.Y.) · 2026Article
- Spatial cellular order underlies locally-confined mechanisms of immune resistance in oropharyngeal cancer.Nature communications · 2026Article
- Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.Cancer cell · 2026Article
- Loss of tumor-infiltrating lymphocytes and poor response to immunotherapy in IDH GOF mutant melanoma.JCI insight · 2026Article
- Hallmarks and correlates of effective adoptive cell immunotherapy for cancer.Nature reviews. Immunology · 2026Review
- Regulatory T cells in cancer and inflammation.Signal transduction and targeted therapy · 2026Review
- Tumor Anti-Angiogenesis Therapy and Its Influence on Immune Cell Function in the Tumor Microenvironment.Cancer medicine · 2026Review
- The Immune Landscape of Acral Melanoma: From Basic to Clinical.Cancer medicine · 2026Review
- GZMK expression within activated intratumoral T-cell subsets reflects differentiation efficiency and predicts response to cancer immunotherapy.NPJ precision oncology · 2026Article
- Review
72 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
27 authors at 7 institutions in 2 countries.
Giacomo OliveiraDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. giacomo_oliveira@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-7435-5603
Kari StromhaugDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nicoletta CieriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1340-6272
J Bryan IorgulescuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1405-3667
Susan KlaegerBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0074-5163
Jacquelyn O WolffCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Suzanna RachimiBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Vipheaviny CheaTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6592-8710
Kate KrauseDepartment of surgery, Massachusetts General Hospital, Boston, MA, USA.
Samuel S FreemanHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8285-0057
Wandi ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shuqiang LiBroad Institute of MIT and Harvard, Cambridge, MA, USA.
David A BraunDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4543-5553
Donna NeubergDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2566-3145
Steven A CarrBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Kenneth J LivakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9105-5856
Dennie T FrederickBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-3355-5267
Edward F FritschDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Megan Wind-RotoloBristol-Myers Squibb, Cambridge, MA, USA.
Nir HacohenHarvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2349-2656
Moshe Sade-FeldmanBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0022-0287
Charles H YoonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1231-3840
Derin B KeskinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Patrick A OttDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4253-943X
Scott J RodigDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Genevieve M BolandHarvard Medical School, Boston, MA, USA.
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. cwu@partners.org.ORCID http://orcid.org/0000-0002-3348-5054
Broad Institute · USDana-Farber Cancer Institute · USBrigham and Women's Hospital · USBoston University · USBristol-Myers Squibb (United States) · USHarvard University · USMassachusetts General Hospital · US
Funding
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4MVirology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI GEORG Michael LAUER · 2009 to 2026
$48.1MCancer Immune Monitoring and Analysis CenterU24CA224331 · NCI · DANA-FARBER CANCER INST · PI FRANK S HODI, Catherine Ju-Ying Wu · 2017 to 2026
$18.4MTraining Program in Nervous System TumorsK12CA090354 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PLOTKIN, SCOTT R · 2001 to 2025
$16.3MTraining Program in Bioinformatics and Integrative GenomicsT32HG002295 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Peter J Park · 2001 to 2026
$15.8MSingle Cell and ImmunogenomicsP01CA229092 · NCI · DANA-FARBER CANCER INST · PI RITZ, JEROME · 2019 to 2023
$13.8MTraining Grant in Molecular Imaging Research (MGH/HMS)T32CA079443 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2000 to 2025
$10.1MPersonal tumor neoantigens for immunity against chronic lymphocytic leukemiaR01CA155010 · NCI · DANA-FARBER CANCER INST · PI Catherine Ju-Ying Wu · 2011 to 2026
$9.6MDissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint InhibitionR01CA229261 · NCI · DANA-FARBER CANCER INST · PI Patrick Alexander Ott · 2018 to 2026
$3.8M(PQ3) The role of damaged DNA in inter-individual variation of tumor immunityR01CA208756 · NCI · BROAD INSTITUTE, INC. · PI HACOHEN, NIR · 2016 to 2020
$2.6MMerkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapyR01CA279391 · NCI · DANA-FARBER CANCER INST · PI Derin B Keskin · 2024 to 2026
$2.2MSingle cell investigation of co-evolution in cancer cells and host cell immune microenvironmentR50CA251956 · NCI · DANA-FARBER CANCER INST · PI Shuqiang Li · 2020 to 2026
$1.4MNCI NIH HHS K12 CA090354NCI NIH HHS P01 CA229092NCI NIH HHS P50 CA101942NCI NIH HHS R01 CA155010NCI NIH HHS R01 CA208756NCI NIH HHS R01 CA229261NCI NIH HHS R01 CA279391NCI NIH HHS R21 CA216772NCI NIH HHS R50 CA251956NCI NIH HHS T32 CA079443NCI NIH HHS U24 CA224331NHGRI NIH HHS T32 HG002295NIAID NIH HHS U19 AI082630
Abstract
Within the tumour microenvironment, CD4
Indexed as
Antigens, NeoplasmCD4-Positive T-LymphocytesMelanomaSkin NeoplasmsAntigen-Presenting CellsHLA AntigensHumansPhenotypeTumor Cells, CulturedTumor MicroenvironmentAntigens, NeoplasmHLA Antigens
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.